ARROWHEAD PHARMACEUTICALS, INC. — Operating Income by Fiscal Year

16 fiscal years, as filed with the SEC; every row links its evidence fact.

Cite as: FACTANKER, https://factanker.com/entity/2d92481f-2552-416a-bb27-0ec95564daae/serie/operating-income

Fiscal year	Operating Income	Period	Evidence
FY 2025	$98.3M	2024-10-01 – 2025-09-30	evidence 0000879407-25-000029
FY 2024	$-601.1M	2023-10-01 – 2024-09-30	evidence 0001628280-24-049277
FY 2023	$-205.0M	2022-10-01 – 2023-09-30	evidence 0001628280-23-040219
FY 2022	$-178.5M	2021-10-01 – 2022-09-30	evidence 0001628280-22-030869
FY 2021	$-149.0M	2020-10-01 – 2021-09-30	evidence 0001564590-21-057888
FY 2020	$-93.2M	2019-10-01 – 2020-09-30	evidence 0001564590-21-057888
FY 2019	$61.2M	2018-10-01 – 2019-09-30	evidence 0001564590-21-057888
FY 2018	$-55.9M	2017-10-01 – 2018-09-30	evidence 0001564590-18-030805
FY 2017	$-37.0M	2016-10-01 – 2017-09-30	evidence 0001564590-17-024834
FY 2016	$-81.7M	2015-10-01 – 2016-09-30	evidence 0001564590-16-030217
FY 2015	$-96.0M	2014-10-01 – 2015-09-30	evidence 0001564590-15-011489
FY 2014	$-53.3M	2013-10-01 – 2014-09-30	evidence 0001564590-14-005961
FY 2013	$-160.0M	2003-05-01 – 2014-03-31	evidence 0001564590-14-001816
FY 2012	$-127.4M	2003-05-01 – 2013-03-31	evidence 0001193125-13-210998
FY 2011	$-105.0M	2003-05-07 – 2012-03-31	evidence 0001193125-12-218387
FY 2010	$-5.8M	2009-10-01 – 2010-09-30	evidence 0001193125-11-347334

Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).

ARROWHEAD PHARMACEUTICALS, INC. — all facts · Revenue · Net Income